Literature DB >> 22508177

Absence of clinically relevant growth acceleration in untreated children with non-classical congenital adrenal hyperplasia.

Karijn J Pijnenburg-Kleizen1, George F Borm, Barto J Otten, Dina A Schott, Erica L van den Akker, Wilhelmina H Stokvis-Brantsma, Paul G Voorhoeve, Boudewijn Bakker, Hedi L Claahsen-van der Grinten.   

Abstract

BACKGROUND/AIMS: In classical congenital adrenal hyperplasia (CAH), elevation of adrenal androgens leads to accelerated growth and bone maturation with compromised adult height. In untreated children with non-classical CAH (NC-CAH), in which adrenal androgens are generally only slightly increased, growth velocity may not be significantly elevated.
METHODS: Twenty-four patients were included and divided into a symptomatic and an asymptomatic group. Height was expressed as height standard deviation scores (HSDS) and corrected for target height (HSDS-THSDS). Bone maturation was expressed as bone age acceleration (BA(c) = bone age - calendar age). Linear mixed models with random factor patient were used for the analysis of growth and bone age.
RESULTS: In symptomatic patients (n = 17), HSDS-THSDS only slightly increased by 0.06 SDS per year (95% CI 0.02-0.10). Mean BA(c) was 2.21 years (SDS 0.66, p < 0.0001). In asymptomatic patients (n = 7), no significant growth acceleration or BA(c) was found.
CONCLUSIONS: In untreated NC-CAH children, growth acceleration is small and generally not visible on their growth charts. BA(c) is more pronounced. Therefore, the absence of an increase in growth velocity does not exclude the diagnosis of NC-CAH. When considering this diagnosis, bone age acceleration should also be taken into account.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22508177     DOI: 10.1159/000337217

Source DB:  PubMed          Journal:  Horm Res Paediatr        ISSN: 1663-2818            Impact factor:   2.852


  5 in total

Review 1.  The way toward adulthood for females with nonclassic congenital adrenal hyperplasia.

Authors:  Georgia Ntali; Sokratis Charisis; Christo F Kylafi; Evangelia Vogiatzi; Lina Michala
Journal:  Endocrine       Date:  2021-04-14       Impact factor: 3.633

Review 2.  Management of congenital adrenal hyperplasia in childhood.

Authors:  Mimi S Kim; Anna Ryabets-Lienhard; Mitchell E Geffner
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-12       Impact factor: 3.243

Review 3.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

4.  Ultralow-dose Dexamethasone to Preserve Endogenous Cortisol Stress Response in Nonclassical Congenital Adrenal Hyperplasia: A New Promising Treatment.

Authors:  Danielle van der Kaay; Erica van den Akker
Journal:  Int J Endocrinol Metab       Date:  2014-07-01

5.  Height outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: Evidence from recent data.

Authors:  Mahdi Kamoun; Mouna Mnif Feki; Mohamed Abid
Journal:  Indian J Endocrinol Metab       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.